Karmanos Cancer Institute first to receive innovative, FDA-approved SoftVue™ Breast Imaging System
Michimich.com/10194525

First-of-its-kind technology designed to improve outcomes for women with dense breast tissue

DETROIT, Sept. 26, 2022 /PRNewswire/ -- The Barbara Ann Karmanos Cancer Institute, the world-renowned, Detroit-based National Cancer Institute-Designated Comprehensive Cancer Center, is the first to receive the SoftVue™ 3D Whole Breast Ultrasound Tomography System (SoftVue™), following its approval by the Food and Drug Administration. Developed by Novi-based Delphinus Medical Technologies, the new and advanced technology was designed to be the screening solution for women with dense breast tissue.

Dense breast tissue is common, affecting 40 percent of women and making them four times more likely to develop breast cancer. Compounding the increased risk, dense breast tissue typically appears as a solid white area on a mammogram, making it difficult to distinguish from masses and other serious abnormalities, missing roughly half of new cancer cases.

When paired with a screening mammogram, SoftVue™ has been shown to identify up to 20 percent more cancers, while also reducing false positives and decreasing unnecessary call-backs and biopsies.

"As a leading cancer center, we are committed to providing our patients with superior diagnostic and screening technology. The development of SoftVue™, in partnership with Delphinus Medical Technologies, will further strengthen our fight against breast cancer that accounts for one in three new cancer diagnoses in women each year," said Brian Gamble, president of the Karmanos Cancer Hospital. "The key to breast cancer survival is early detection and this new screening device will be lifesaving for so many women in our community. Our clinical team worked hard for many years to develop this transformational technology, and we are proud to be the first in the world to offer SoftVue™ to our patients."

More on Michimich.com

• Strategic Partnerships with Defiant Space Corp and Emtel Energy USA Powerfully Enhance Solar Tech Leader with NASA Agreements: Ascent Solar $ASTI
• 120% Revenue Surge with Four Straight Profitable Quarters Signal a Breakout in the Multi-Billion Dollar Homebuilding Market: Innovative Designs $IVDN
• Leading Venture Capital Firms Recognize Wzzph Exchange's Technical Architecture and Security Framework as Industry Benchmark
• DivX Unveils Major DivX Software Update: Seamless Video Sharing and Customizable Playback Now Available
• Nespolo Mechanical Helps New Mexico Families Save Thousands on Heating Costs This Fall

Dedicated to the mission of leading in transformative cancer care, research and education, in 2009, Karmanos launched Delphinus Medical Technologies. The two organizations have since worked on various prototypes and conducted dozens of clinical trials to develop the state-of-the-art technology, demonstrating its ability to detect the presence of malignant and benign masses in women with dense breasts safely and more accurately.

SoftVue™, used as an adjunct to mammography, allows women with dense breast tissue to have both cancer screenings during a single appointment. Taking approximately eight to 10 minutes, a SoftVue™ mammogram uses warm water and ultrasound technology to create a 3D image of the whole breast to detect the presence of cancer in its earliest stages — including masses in dense breast tissue often missed by mammography alone — while avoiding radiation exposure and compression, allowing the radiologist to make a more accurate diagnosis.

"The team at Karmanos has contributed deeply to the creation of our breakthrough SoftVue™ ultrasound tomography system, and we are thrilled to announce that they placed the first order and will be the first in the world to offer SoftVue™," said Mark Forchette, president & CEO of Delphinus Medical Technologies, Inc. "We are excited about our next steps together to provide a new solution for the unmet needs and challenges of dense breast screening, and to share our proven clinical benefits with their patients."

The SoftVue™ System will be available to patients at Karmanos Cancer Institute before the end of the year.  To learn more about the technology, its benefits and request an appointment, visit karmanos.org/softvue.

About the Barbara Ann Karmanos Cancer Institute
Karmanos Cancer Institute is a leader in transformative cancer care, research and education through courage, commitment and compassion. The Karmanos vision is a world free of cancer. As part of McLaren Health Care, Karmanos is the largest provider of cancer care and research in Michigan. For more than 75 years, the administrative and research headquarters, along with the premier specialty cancer hospital, have been located in downtown Detroit. With 16 network sites, Karmanos delivers world-renowned care and access to clinical trials throughout Michigan and northern Ohio. The National Cancer Institute recognizes Karmanos as one of the best cancer centers in the nation with a comprehensive cancer center designation. Its academic partnership with the Wayne State University School of Medicine provides the framework for cancer research and education – defining new standards of care and improving survivorship. For more information, call 1-800-KARMANOS (800-527-6266) or visit www.karmanos.org. Follow Karmanos on Facebook, Twitter, LinkedIn and YouTube.

More on Michimich.com

• Leading Digital Finance Platform YNQTL Launches Revolutionary Web3 Digital Asset Trading Platform
• IDCXS Addresses Crypto Trading Pain Points with 2 Million TPS Processing and Multi-Layer Security Architecture
• Bridging Traditional Finance and Web3 Innovation: BLFCW Announces Strategic Vision for Regulated Web3 Economy
• NKSCX Responds to "Coordinated Smear Campaign" as Anonymous Critics Emerge Following Regulatory Milestones
• Broadway Gala Honored Also an Italian

SOURCE Karmanos Cancer Institute

---

Show All News | Report Violation